Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma
Peter Martin(Northwestern University), John P. Leonard(New York University), Robin Joyce(Beth Israel Deaconess Medical Center), Jeff Szer(The Royal Melbourne Hospital), Jonathan W. Friedberg(University of Rochester), Saurabh Rajguru(UW Health University Hospital), Ari M. Vander Walde(City of Hope), Bryn Pressnail(Royal Victoria Regional Health Centre), Jordan A. Herst(Health Sciences North), Fernando Cabanillas(University of Puerto Rico, Medical Sciences Campus), Nancy L. Bartlett(Washington University in St. Louis), Bruce D. Cheson(Center for Cancer and Blood Disorders), Ann S. LaCasce(Otsuka (Japan)), Mitchell R. Smith, Zhengming Chen(Cornell University), Bernard Lemieux(Centre Hospitalier Universitaire Sainte-Justine), Michael E. Williams(University of Virginia Health System), Richard H. van der Jagt(Ottawa Hospital), Michael Bär(Stamford Hospital), Anthony J. Dodds(St Vincent's Hospital Sydney), Paul G. Montgomery(St. Luke's Mountain States Tumor Institute), Kristen N. Ganjoo(Stanford Medicine), Katherine Robinson(Queen Elizabeth II Health Sciences Centre), Tricia Ellis(Cornell University)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k